Journal article
Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
- Abstract:
-
Objective
Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient perspective.Methods
This phase 2, double-blind trial (NCT03881059) randomized patients with active PsA 1:1:1 to deucravacitinib 6 mg once daily (QD), 12 mg QD, or placebo, for 16 weeks. Key secondary end points were changes from baseline (CFBs) at week 16 in Health ... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 452.0KB, Terms of use)
-
- Publisher copy:
- 10.1002/acr.25333
Authors
Bibliographic Details
- Publisher:
- Wiley
- Journal:
- Arthritis Care and Research More from this journal
- Publication date:
- 2024-05-07
- Acceptance date:
- 2024-03-25
- DOI:
- EISSN:
-
2151-4658
- ISSN:
-
2151-464X
Item Description
- Language:
-
English
- Pubs id:
-
1728768
- Local pid:
-
pubs:1728768
- Deposit date:
-
2024-03-04
Terms of use
- Copyright holder:
- Strand et al.
- Copyright date:
- 2024
- Rights statement:
- © 2024 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record